The Drug Discovery and Development Industry in India-Two Decades of Proprietary Small-Molecule R&D

Overview

Journal ChemMedChem

Specialties Chemistry
Pharmacology

Date 2017 May 3

PMID 28464443

Citations 12

Authors

Edmond Differding

Affiliations

Soon will be listed here.

Abstract

This review provides a comprehensive survey of proprietary drug discovery and development efforts performed by Indian companies between 1994 and mid-2016. It is based on the identification and detailed analysis of pharmaceutical, biotechnology, and contract research companies active in proprietary new chemical entity (NCE) research and development (R&D) in India. Information on preclinical and clinical development compounds was collected by company, therapeutic indication, mode of action, target class, and development status. The analysis focuses on the overall pipeline and its evolution over two decades, contributions by type of company, therapeutic focus, attrition rates, and contribution to Western pharmaceutical pipelines through licensing agreements. This comprehensive analysis is the first of its kind, and, in our view, represents a significant contribution to the understanding of the current state of the drug discovery and development industry in India.

Citing Articles

Rising pharmaceutical innovation in the Global South: a landscape study.

Vieira M, Andia T, Karim O, Srishti S, Pineda S, Ruiz A J Pharm Policy Pract. 2023; 16(1):155.

PMID: 38012700 PMC: 10680326. DOI: 10.1186/s40545-023-00669-3.

Navigating the open innovation paradox: an integrative framework for adopting open innovation in pharmaceutical R&D in developing countries.

Bhatnagar B, Dorfler V, MacBryde J J Technol Transf. 2022; :1-45.

PMID: 35996639 PMC: 9386677. DOI: 10.1007/s10961-022-09958-6.

ICMR National Virtual Centre for Clinical Pharmacology with Network of Rational Use of Medicines & Product Development Centres.

Kshirsagar N, Kaul R, Kumar V Indian J Med Res. 2022; 154(5):665-668.

PMID: 35532584 PMC: 9210526. DOI: 10.4103/ijmr.IJMR_1857_19.

Anti-Diabetic Activity of Bioactive Compound Extracted from Fruit: In-Vitro and Molecular Docking Approaches.

Khalid M, Alqarni M, Alsayari A, Foudah A, Aljarba T, Mukim M Plants (Basel). 2022; 11(4).

PMID: 35214895 PMC: 8880729. DOI: 10.3390/plants11040562.

A two-year evaluation of the minutes of Investigational New Drug committee meetings.

Raj J, Gogtay N, Thatte U Perspect Clin Res. 2021; 12(4):199-202.

PMID: 34760647 PMC: 8525788. DOI: 10.4103/picr.PICR_83_19.

References

Mohanan A, Gupta R, Dubey A, Jagtap V, Mandhare A, Gupta R . TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats. Int J Hypertens. 2012; 2011:751513. PMC: 3253485. DOI: 10.4061/2011/751513. View

Addepalli M, Ray K, Kumar B, Ramnath R, Chile S, Rao H . RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. Gene Ther. 2009; 17(3):352-9. DOI: 10.1038/gt.2009.155. View

Chakrabarti R, Vikramadithyan R, Misra P, Hiriyan J, Raichur S, Damarla R . Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Br J Pharmacol. 2003; 140(3):527-37. PMC: 1574054. DOI: 10.1038/sj.bjp.0705463. View

Singh H, Chawla A, Kapoor V . Medicinal chemistry research in India. Prog Med Chem. 1985; 22:243-66. DOI: 10.1016/s0079-6468(08)70232-7. View

Fishburn C . Translational research: the changing landscape of drug discovery. Drug Discov Today. 2012; 18(9-10):487-94. DOI: 10.1016/j.drudis.2012.12.002. View

Butler M, Robertson A, Cooper M . Natural product and natural product derived drugs in clinical trials. Nat Prod Rep. 2014; 31(11):1612-61. DOI: 10.1039/c4np00064a. View

Rivers E, Mancera R . New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov Today. 2008; 13(23-24):1090-8. DOI: 10.1016/j.drudis.2008.09.004. View

Al-Lahham A, de Souza N, Patel M, Reinert R . Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. J Antimicrob Chemother. 2005; 56(6):1130-3. DOI: 10.1093/jac/dki361. View

Balganesh T, Kundu T, Chakraborty T, Roy S . Drug discovery research in India: current state and future prospects. ACS Med Chem Lett. 2014; 5(7):724-6. PMC: 4094254. DOI: 10.1021/ml500183c. View

10.

Dyke H . Novel 5,6-dihydropyrazolo[3,4-E][1,4]diazepin-4 (1H)-one derivatives for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Ther Pat. 2010; 17(9):1183-9. DOI: 10.1517/13543776.17.9.1183. View

11.

Jamadarkhana P, Chaudhary A, Chhipa L, Dubey A, Mohanan A, Gupta R . Treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates ischemic acute kidney injury. Am J Nephrol. 2012; 36(3):208-18. DOI: 10.1159/000341870. View

12.

Rezaie R, McGahan A, Daar A, Singer P . Innovative drugs and vaccines in China, India and Brazil. Nat Biotechnol. 2012; 30(10):923-6. DOI: 10.1038/nbt.2380. View

13.

Datla P, Kalluri M, Basha K, Bellary A, Kshirsagar R, Kanekar Y . 9,10-dihydro-2,5-dimethoxyphenanthrene-1,7-diol, from Eulophia ochreata, inhibits inflammatory signalling mediated by Toll-like receptors. Br J Pharmacol. 2010; 160(5):1158-70. PMC: 2936025. DOI: 10.1111/j.1476-5381.2010.00780.x. View

14.

Agrawal R, Jain P, Dikshit S . Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist. Mini Rev Med Chem. 2012; 12(2):87-97. DOI: 10.2174/138955712798995048. View

15.

Joshi D, Gupta R, Dubey A, Shiwalkar A, Pathak P, Gupta R . TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol. 2009; 54(1):72-81. DOI: 10.1097/FJC.0b013e3181ac3a34. View

16.

Balasubramanian V, Solapure S, Iyer H, Ghosh A, Sharma S, Kaur P . Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother. 2013; 58(1):495-502. PMC: 3910779. DOI: 10.1128/AAC.01903-13. View

17.

Boyd A, Bartlett P, Lackmann M . Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014; 13(1):39-62. DOI: 10.1038/nrd4175. View

18.

Hiriyan J, Shivarudraiah P, Gavara G, Annamalai P, Natesan S, Sambasivam G . Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models. Anticancer Res. 2015; 35(1):229-37. View

19.

Kalluri M, Datla P, Bellary A, Basha K, Sharma A, Sharma A . Novel synthetic gluco-disaccharide RSCL-0409--a lipopolysaccharide-induced Toll-like receptor-mediated signalling antagonist. FEBS J. 2010; 277(7):1639-52. DOI: 10.1111/j.1742-4658.2010.07589.x. View

20.

de Souza Mendes C, Antunes A . Pipeline of Known Chemical Classes of Antibiotics. Antibiotics (Basel). 2016; 2(4):500-34. PMC: 4790266. DOI: 10.3390/antibiotics2040500. View